Chlormezanone

• Catalog No.: DB01178
• CAS Number: 80-77-3
• M. F.: C11H12ClNO3S
• M. W.: 273.73588

SYNONYMS

• IUPAC name: 2-(4-chlorophenyl)-3-methyl-1$l^{6},3-thiazinane-1,1,4-trione
• IUPAC Traditional name: chlormezanone
• Brand Name: Myolespen; Alinam; Bisina; Mio-Sed; Muskel-Trancopal; Rexan; Rilaquil; Rilax; Rillasol; Suprotan; Trancopal; Tranrilax; Transanate; Banabil-sintyal; Banabin; Banabin-Sintyal; Banabin-syntyal; Chlomedinon; Clorilax; Lobak; Miorilax; Muskel; Phenarol; Rilasol; Rilassol; Supotran; Tanafol; Rilansyl; Trancote
• Synonyms: Clormetazon; Dichloromezanone; Clormetazanone; Clormezanona [INN-Spanish]; Chlormezanone [BAN:INN:JAN]; Chlormezanon; Chlormezanonum [INN-Latin]; Chlormethazanone; Chlormethazone; Clormezanone [DCIT]; Dichloromethazanone; dl-Chlormezanone

DATABASE IDS

• PubChem CID: 2717
• PubChem SID: 46505352
• CAS Number: 80-77-3

PROPERTIES

• Hydrophobicity(logP): 1.3
• Solubility: 2500 mg/L (hardly soluble)

DETAILS

Description (English)

• Drug Groups: approved; withdrawn
• Description: A non-benzodiazepine that is used in the management of anxiety. It has been suggested for use in the treatment of muscle spasm. [PubChem]
• Indication: Used in the management of anxiety and in the treatment of muscle spasm.
• Pharmacology: Chlormezanone is a non-benzodiazepine muscle relaxant. It was discontinued worldwide in 1996 by its manufacturer due to confirmed serious and rare cutaneous reactions (toxic epidermal necrolysis).
• Toxicity: Symptoms of overdose include drowsiness, weakness, nausea, dizziness, abdominal pain, cerebral oedema and renal tubular necrosis, hyperglycaemia and hypoglycaemia, liver damage, encephalopathy, coma and death.
• Affected Organisms: Humans and other mammals
• References: Wollina U, Hipler UC, Seeling A, Oelschlager H: Investigations of interactions of chlormezanone racemate and its enantiomers on human keratinocytes and human leucoytes in vitro. Skin Pharmacol Physiol. 2005 May-Jun;18(3):132-8. [Pubmed] ; Seeling A, Oelschlager H, Rothley D: [Important pharmaceutical-chemical characteristics of the central muscle relaxant chlormezanone] Pharmazie. 2000 Apr;55(4):293-6. [Pubmed] ; Oelschlager H, Klinger W, Rothley D, Seeling A, Bockhard H, Hofmann B, Machts H, Riederer H, Rackur H: [Cleavage and biotransformation of the central muscle relaxant chlormezanone] Pharmazie. 1998 Sep;53(9):620-4. [Pubmed] ; Gautier V, Vincon G, Demotes-Mainard F, Albin H: [Pharmacokinetics of chlormezanone in healthy volunteers] Therapie. 1990 Jul-Aug;45(4):315-9. [Pubmed]
• External Links: Wikipedia

REFERENCES

• Oelschlager H, Klinger W, Rothley D, Seeling A, Bockhard H, Hofmann B, Machts H, Riederer H, Rackur H: [Cleavage and biotransformation of the central muscle relaxant chlormezanone] Pharmazie. 1998 Sep;53(9):620-4. Pubmed
• Gautier V, Vincon G, Demotes-Mainard F, Albin H: [Pharmacokinetics of chlormezanone in healthy volunteers] Therapie. 1990 Jul-Aug;45(4):315-9. Pubmed
• Wollina U, Hipler UC, Seeling A, Oelschlager H: Investigations of interactions of chlormezanone racemate and its enantiomers on human keratinocytes and human leucoytes in vitro. Skin Pharmacol Physiol. 2005 May-Jun;18(3):132-8. Pubmed
• Seeling A, Oelschlager H, Rothley D: [Important pharmaceutical-chemical characteristics of the central muscle relaxant chlormezanone] Pharmazie. 2000 Apr;55(4):293-6. Pubmed